Literature DB >> 11014221

Neuroendocrine cell type-specific and inducible expression of the chromogranin B gene: crucial role of the proximal promoter.

N R Mahapatra1, M Mahata, A K Datta, H H Gerdes, W B Huttner, D T O'Connor, S K Mahata.   

Abstract

Chromogranin B, a soluble acidic secretory protein, is widely distributed in neuroendocrine and neuronal cells, although not in other cell types. To identify the elements governing such widespread, yet selective, expression of the gene, we characterized the isolated mouse chromogranin B promoter. 5'-Promoter deletions localized neuroendocrine cell type-specific expression to the proximal chromogranin B promoter (from -216 to -91 bp); this region contains an E box (at [-206 bp]CACCTG[-201 bp]), four G/C-rich regions (at [-196 bp]CCCCGC[-191 bp], [-134 bp]CCGCCCGC[-127 bp], [-125 bp]GGCGCCGCC[-117 bp], and [-115 bp]CGGGGC[-110 bp]), and a cAMP response element (CRE; at [-102 bp]TGACGTCA[-95 bp]). A 60-bp core promoter region, defined by an internal deletion from - 134 to -74 bp upstream of the cap site and spanning the CRE and three G/C-rich regions, directed tissue-specific expression of the gene. The CRE motif directed cell type-specific expression of the chromogranin B gene in neurons, whereas three of the G/C-rich regions played a crucial role in neuroendocrine cells. Both the endogenous chromogranin B gene and the transfected chromogranin B promoter were induced by preganglionic secretory stimuli (pituitary adenylyl cyclase-activating polypeptide, vasoactive intestinal peptide, or a nicotinic cholinergic agonist), establishing stimulus-transcription coupling for this promoter. The adenylyl cyclase activator forskolin, nerve growth factor, and retinoic acid also activated the chromogranin B gene. Secretagogue-inducible expression of chromogranin B also mapped onto the proximal promoter; inducible expression was entirely lost upon internal deletion of the 60-bp core (from 134 to -74 bp). We conclude that CRE and G/C-rich domains are crucial determinants of both cell type-specific and secretagogue-inducible expression of the chromogranin B gene.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11014221     DOI: 10.1210/endo.141.10.7725

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  4 in total

1.  Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog.

Authors:  Nitish R Mahapatra; Daniel T O'Connor; Sucheta M Vaingankar; Amiya P Sinha Hikim; Manjula Mahata; Saugata Ray; Eugenie Staite; Hongjiang Wu; Yusu Gu; Nancy Dalton; Brian P Kennedy; Michael G Ziegler; John Ross; Sushil K Mahata
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

2.  Autonomic function in hypertension; role of genetic variation at the catecholamine storage vesicle protein chromogranin B.

Authors:  Kuixing Zhang; Fangwen Rao; Brinda K Rana; Jiaur R Gayen; Federico Calegari; Angus King; Patrizia Rosa; Wieland B Huttner; Mats Stridsberg; Manjula Mahata; Sucheta Vaingankar; Vafa Mahboubi; Rany M Salem; Juan L Rodriguez-Flores; Maple M Fung; Douglas W Smith; Nicholas J Schork; Michael G Ziegler; Laurent Taupenot; Sushil K Mahata; Daniel T O'Connor
Journal:  Circ Cardiovasc Genet       Date:  2009-02

3.  Human heart rate: heritability of resting and stress values in twin pairs, and influence of genetic variation in the adrenergic pathway at a microribonucleic acid (microrna) motif in the 3'-UTR of cytochrome b561 [corrected].

Authors:  Kuixing Zhang; Dekker C Deacon; Fangwen Rao; Andrew J Schork; Maple M Fung; Jill Waalen; Nicholas J Schork; Caroline M Nievergelt; Neil C Chi; Daniel T O'Connor
Journal:  J Am Coll Cardiol       Date:  2013-10-16       Impact factor: 24.094

4.  Functional promoter polymorphisms govern differential expression of HMG-CoA reductase gene in mouse models of essential hypertension.

Authors:  Parshuram J Sonawane; Bhavani S Sahu; Binu K Sasi; Parimala Geedi; Govinda Lenka; Nitish R Mahapatra
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.